2C
HBIO icon

272 Capital’s Harvard Bioscience HBIO Stock Holding History

272 Capital’s Portfolio HBIO Stock Details HBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-135,140
Closed -$2.85M – 44
2024
Q4 		$2.85M Sell
135,140
-18,442
-12% -$424K 2.7% 14
2024
Q3 		$4.13M Hold
153,582
– – 2.36% 15
2024
Q2 		$4.38M Sell
153,582
-129,912
-46% -$4.56M 2.19% 15
2024
Q1 		$12M Sell
283,494
-10,434
-4% -$469K 4.8% 4
2023
Q4 		$15.7M Sell
293,928
-32,372
-10% -$1.46M 5.31% 4
2023
Q3 		$14M Buy
326,300
+20,004
+7% +$923K 5.58% 3
2023
Q2 		$16.8M Sell
306,296
-34,584
-10% -$1.9M 6.18% 4
2023
Q1 		$14.3M Buy
340,880
+22,150
+7% +$657K 5.93% 2
2022
Q4 		$8.83M Buy
318,730
+147,206
+86% +$3.63M 3.95% 7
2022
Q3 		$4.39M Buy
171,524
+17,059
+11% +$564K 2.36% 11
2022
Q2 		$5.56M Buy
154,465
+64,621
+72% +$2.92M 2.66% 10
2022
Q1 		$5.58M Buy
89,844
+29,205
+48% +$1.73M 2.67% 10
2021
Q4 		$4.28M Buy
+60,639
New +$4.31M 2.06% 12

Other funds holding HBIO

AE
AMH Equity Great Neck, New York $80.3M AUM 78.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HP
Harvey Partners Tarrytown, New York $1.26B AUM 64.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

272 Capital's HBIO Position: Q1 2025 in Review

272 Capital sold out of Harvard Bioscience (HBIO) in Q1 2025, closing a stake of 135,140 shares — an estimated $2.85M sold.

272 Capital first reported a position in HBIO in Q4 2021 and held it in 13 quarters. The position peaked at $16.8M in Q2 2023. 91 funds tracked by Wall St. Rank hold HBIO as of Q1 2025.

  • 272 Capital reported no remaining Harvard Bioscience position as of Q1 2025 after selling out during the quarter.
  • 272 Capital sold 135,140 Harvard Bioscience shares in Q1 2025, an estimated $2.85M.
  • 272 Capital first reported a position in Harvard Bioscience in Q4 2021 and held it in 13 quarters.
  • 272 Capital's Harvard Bioscience position peaked at $16.8M in Q2 2023.
  • 91 funds tracked by Wall St. Rank held Harvard Bioscience as of Q1 2025.

Based on 272 Capital's 13F filing for Q1 2025, filed 15 May 2025.